ArrayPatch Ltd is thrilled to announce that it has successfully raised €3,000,000 in its latest funding round—a significant milestone for the company and a robust vote of confidence in its pioneering technology and vision. As a pre-revenue, preclinical spin-out from University College Cork, Ireland, ArrayPatch is focused on transforming the landscape of healthcare by providing professionals with superior treatment options that ultimately improve patient outcomes. Central to this vision is the company’s innovative DerMap patent technology, a unique microneedle platform poised to revolutionize treatment methods. The first product harnessing this novel technology is aimed at addressing stubborn fungal infections of the nail, delivering a much-needed alternative to existing treatments that have long challenged both patients and clinicians alike.
The funds raised will be strategically allocated towards expediting the development of the nail treatment product, facilitating rigorous preclinical studies, and setting the foundation for future clinical trials. Moreover, this financial boost empowers ArrayPatch to expand its research pipeline and business case evaluations for additional products targeting critical areas such as skin cancer, psoriasis, and hormone replacement therapy. With these developments, ArrayPatch Ltd is not only strengthening its current product portfolio but also paving the way for more groundbreaking therapies that could transform patient care across multiple disciplines. This funding round marks a new chapter for the company, reinforcing its commitment to medical innovation and its core mission of advancing healthcare outcomes. We are excited about the opportunities ahead and look forward to updating our community on our progress in bringing these promising treatments from the lab to the clinic.
